(Q48891121)

English

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.

scientific article published on 22 December 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Thomas Kurt Eigentler

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Kilian Wistuba-Hamprecht

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Benjamin Weide

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Alexander Martens

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Henning Zelba

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Ludwig Maier

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Bernhard D Klumpp

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Daniel Soffel

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Hans-Peter Lipp

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

publication date

22 December 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

66

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

441-449

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4: new insights into its biological function and use in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

The interaction properties of costimulatory molecules revisited.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Increased survival from stage IV melanoma associated with fewer regulatory T Cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

High response rate after intratumoral treatment with interleukin-2

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Identifiers

10.1007/S00262-016-1944-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48891121&oldid=2209858669"